Scn element

Scn element DEFAULT

Open Access


  • Patty C. Kandalepas,
  • Jennifer W. Mitchell,
  • Martha U. Gillette
  • Patty C. Kandalepas, 
  • Jennifer W. Mitchell, 
  • Martha U. Gillette



Melatonin is released from the pineal gland into the circulatory system at night in the absence of light, acting as “hormone of darkness” to the brain and body. Melatonin also can regulate circadian phasing of the suprachiasmatic nucleus (SCN). During the day-to-night transition, melatonin exposure advances intrinsic SCN neural activity rhythms via the melatonin type-2 (MT2) receptor and downstream activation of protein kinase C (PKC). The effects of melatonin on SCN phasing have not been linked to daily changes in the expression of core genes that constitute the molecular framework of the circadian clock. Using real-time RT-PCR, we found that melatonin induces an increase in the expression of two clock genes, Period 1 (Per1) and Period 2 (Per2). This effect occurs at CT 10, when melatonin advances SCN phase, but not at CT 6, when it does not. Using anti-sense oligodeoxynucleotides (α ODNs) to Per 1 and Per 2, as well as to E-box enhancer sequences in the promoters of these genes, we show that their specific induction is necessary for the phase-altering effects of melatonin on SCN neural activity rhythms in the rat. These effects of melatonin on Per1 and Per2 were mediated by PKC. This is unlike day-active non-photic signals that reset the SCN clock by non-PCK signal transduction mechanisms and by decreasing Per1 expression. Rather, this finding extends roles for Per1 and Per2, which are critical to photic phase-resetting, to a nonphotic zeitgeber, melatonin, and suggest that the regulation of these clock gene transcripts is required for clock resetting by diverse regulatory cues.

Citation: Kandalepas PC, Mitchell JW, Gillette MU (2016) Melatonin Signal Transduction Pathways Require E-Box-Mediated Transcription of Per1 and Per2 to Reset the SCN Clock at Dusk. PLoS ONE 11(6): e0157824.

Editor: Shin Yamazaki, University of Texas Southwestern Medical Center, UNITED STATES

Received: April 21, 2013; Accepted: June 6, 2016; Published: June 30, 2016

Copyright: © 2016 Kandalepas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by The National Heart, Lung and Blood Institute (HL086870) and the National Science Foundation (IOS 1354913). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.


A cyclic pattern of cellular events within the mammalian suprachiasmatic nucleus (SCN) conveys time-of-day information to target organs. Neurochemical inputs relaying information about environmental state, including the pineal hormone melatonin, can modulate the timing of the SCN clock. A high density of melatonin receptors within SCN cells indicates that this locale is a target for melatonin action [1,2,3]. Sensitivity of the SCN to melatonin occurs predominantly during the day-to-night (dusk) and night-to-day (dawn) transitions [1,4]. At these times, melatonin advances the phase of neural activity rhythms generated within the SCN via a protein kinase C (PKC)-dependent pathway that acts downstream of the melatonin type-2 (MT2) receptor [5,6,7]. Beyond this, little is understood about the mechanism by which melatonin alters circadian timekeeping.

Light encountered at night is another potent stimulus that shifts intrinsic clock phasing, realigning endogenous rhythms with the cycle of day and night. The resetting action of light on the SCN involves signals from the eye that are transmitted to the SCN where they alter expression of clock genes involved in circadian rhythm generation. In mammals, two genes, Clock and Bmal1, represent the positive elements of a molecular feedback loop [8,9]. They encode transcription factors that heterodimerize in the cytoplasm and translocate to the nucleus to induce the expression of target genes that contain E-box cis-acting regulatory enhancer sequences [9,10]. These include the Period (Per1, Per2, Per3) and Cryptochrome (Cry1 and Cry2) genes, the negative elements of the circadian feedback loop [11,12], which associate and feedback into the nucleus to repress their own transcription [13]. Activation of Per1 transcription is a molecular hallmark of the SCN response to nocturnal light, and is necessary for nocturnal light, or glutamate, the key neurotransmitter from the eye to the SCN, to alter SCN phasing [14,15,16]

Using methods that established the relationship between photic signals and their engagement with the SCN circadian clock, we investigated the potential interaction between melatonin and the molecular oscillatory machinery. Using quantitative real-time RT-PCR, we found that melatonin application to the SCN brain slice significantly altered the expression of the clock genes Per1 and Per2, but not Bmal1, at CT 10, subjective dusk, the SCN window of sensitivity to effects of melatonin on clock phase. Conversely, the same experiment conducted mid-subjective day, CT 6, when melatonin has no effect on SCN phasing, did not detect changes in Per1 and Per2, although Bmal1 was reduced. Both the melatonin-induced phase advance of SCN neuronal activity rhythms and regulation of these mRNAs were abolished by specific inhibition of PKC. Moreover, using anti-sense oligodeoxynucleotide (α ODN) decoys, we demonstrate that transcriptional activation of Per1 and Per2 via E-box enhancer sequences is necessary for the temporally specific phase shifts induced by melatonin at CT 10. Our findings support a link between melatonin-induced signal transduction pathways activating necessary Per1 and Per2 transcription and clock resetting in the SCN by melatonin at dusk.

Materials and Methods

Animal Welfare Assurance

All experiments were performed in compliance with the Guide for Care and Use of Laboratory Animals of the National Institutes of Health and approved by the Institutional Animal Care and Use Committee at the University of Illinois at Urbana-Champaign (Animal Welfare Assurance #A3118-01).

SCN brain slice preparation and circadian time

Long-Evans rats from our inbred colony (LE/BluGill) [17] were maintained on a 12:12 h LD cycle for at least 2 weeks before experimentation. Male animals were between 6–12 weeks of age at the time of use, and received food and water ad libitum. For acute brain slice studies, rats were removed from the colony during daytime only (≥ 2 h before the onset of the dark phase) to avoid phase shifts during preparation [18], and quickly decapitated. A 500 μm-thick coronal brain slice containing the paired SCN was prepared and placed at the interface of a Hatton-style brain slice chamber [19]. For qPCR studies, brain slices were reduced in size using a corer (2 mm diameter) to minimize non-SCN tissue, and placed into a brain slice chamber. Slices were perifused continuously with Earle’s balanced salt solution (EBSS) plus 24.6 mM glucose, 26.2 mM sodium bicarbonate, 5 mg/L gentamicin and saturated with 95% O2 / 5% CO2 at 37°C (final pH 7.2). Slices were under constant illumination and allowed to equilibrate at least 2 h before treatment. Because brain slices are maintained in constant conditions where the clock functions with a period of ~24 h without external time cues, the time of lights-on in the donor colony is designated as circadian time 0 (CT 0). Thus, subjective day (CT 0–12) corresponds to the light portion of the donor’s former lighting schedule, and subjective night (CT 12–24) corresponds to the dark portion of the donor’s cycle.

Experimental treatments

Melatonin (EMD Chemicals, Gibbstown, NJ) was dissolved at 1 mM in 95% EtOH, and serially diluted to 1 nM in warmed EBSS at the time of use. At the appropriate CT (CT 6 or CT 10), perifusion of the slices was stopped, and a volume of 1 μl containing 1 nM melatonin was applied directly to each SCN for 10 min, after which the SCN was washed with fresh EBSS and perifusion was resumed. Control slices were maintained in parallel in a separate brain slice chamber and treated with 1 μl of EBSS/ SCN for 10 min at CT 6 or 10.

To assess the contribution of PKC to the effect of melatonin, the PKC inhibitor chelerythrine chloride (CC, EMD Chemicals, Gibbstown, NJ) was used. For inhibitor studies, CC was dissolved at 50 mM in 100% dimethyl sulfoxide (DMSO) and diluted to 0.25 mM, 0.05% DMSO in warmed EBSS. CC was bath-applied to the brain slice 20 min before treatment, and then either melatonin or EBSS was applied to the SCN for an additional 10 min. CC at this concentration is sufficient to abolish both melatonin-induced PKC phosphotransferase activity and MT2 receptor-mediated phase advances of SCN rhythm in neuronal firing without long-term effects on SCN tissue viability [5,6,20]. For antisense oligodeoxynucleotide (αODN) treatments, slices were pre-treated with αODN for Per1 or Per2 for 2 h before the start of melatonin treatment. Perifusion was stopped and the bath media was manually exchanged with medium containing the αODN. To control for non-specific effects of incubation with ODNs, slices were treated in the same manner using a missense ODN sequence.

For E-box ODN treatments, 1 μM of the αODN decoy or missense ODN was bath applied to the brain slice from CT 8–10, and then either melatonin or EBSS was applied at CT 10 for an additional 10 min. At this concentration E-box ODN decoy, but not missense ODN, inhibited the glutamate-induced phase shifts in SCN neuronal activity during early and late night in the rat SCN [21]. At the conclusion of the treatments, the medium in the brain slice chamber was replaced with fresh EBSS, and perifusion was resumed.

Experimental nucleotide sequence design

Published sequences of αODN against the 5’ start site of Per1 (5’-TAGGGGACCACTCATGTCT-3’) [14,15,22,23,24] and Per2 (5’-TATCCATTCATGTCG-3’) [15,22,23] were used (the initiation site is underlined). As a control, corresponding missense ODN also was used (Per1 missense, 5'-AGCTGCAGCTCTCGGAATT-3’; Per2 missense, 5’-ACCATGTTACCTGACCTGT-3’) [22,23]. Missense and antisense ODN contain equal GC content. These sequences have been published and successfully used by both our lab [15,25] and others [14,22,23,24] in studies investigating Per1 and Per2 involvement in the mammalian clock in rodents.

The E-box decoy was designed and previously used by our lab [25,26]. Briefly, the E-box decoy contains three E-box sequences (5’-CACGTG-3’) plus 6 bp flanking sequence (per E-box) from between exon 1A and exon 1B of the mouse Per1 promoter (5’- TTTAGCCACGTGACAGTGTAAGCACACGTGGGCCCTCAAGTC CACGTGCAGGGA-3’). The missense control ODN has the same overall nucleotide composition as decoy ODN, but the 5’-CACGTG-3’ E-box sequence has been inverted (5’- TTTAGCGTGCACACAGTGTAAGCAGTGCACGGCCCTCAAGTCGTGCACCAGGGA -3’). Sequences flanking the core E-box remain unaltered in missense ODN.

Isolation of SCN 2.2 nuclear extracts and electrophoretic mobility shift assay

SCN 2.2 cells were scraped in wash solution (15 mM HEPES, pH 7.2, 250 mM sucrose, 60 mM KCl, 10 mM NaCl, 1 mM EGTA, 5 mM EDTA, 2 mM NaF, 2 mM NaPPi, 1 mM phenylmethylsulfonyl fluoride, 5 μM mycrocystin-LR) and centrifuged at 2000 × g for 10 min. Pellets were resuspended in cell lysis solution (10 mM HEPES, pH 7.2, 1.5 mM MgCl2, 10 mM KCl, 1 mM phenylmethylsulfonyl fluoride 5 μM microcystin-LR, 2 mM NaF, 2 mM NaPPi) and centrifuged at 4000 × g for 10 min to isolate nuclei. The pellet was re-suspended in nuclei lysis solution (100 mM HEPES, pH 7.2, 1.5 mM MgCl2, 1 mM EDTA, 800 mM NaCl, 2 mM NaF, 2 mM NaPPi, 1 mM phenylmethylsulfonyl fluoride, 5 μM microcystin-LR, 25% glycerol) and centrifuged at 14,000 × g for 30 min to pellet debris. 5 μg of nuclear extract from SCN 2.2 cells transfected with E-box decoy or E-box missense ODN using Effectene (Qiagen) was incubated in 100 ng/ μl poly(dI-dC), 300 nM dithiothreitol, 12 mM Tris pH 8.0, 2 mM MgCl2, 60 mM KCl, 120 nM EDTA, pH 8.0, 12.5% glycerol for 30 min at 4°C. 10,000 cpm of 32P-end-labeled E-box decoy was added and incubated at 37°C for 10 min. The samples were separated by 8% PAGE and exposed on Kodak MS Film.

Quantitative real-time RT-PCR (qPCR)

Brain slices were collected at 30 and 120 min following application of melatonin or EBSS (control), and frozen directly on dry ice. Samples were stored at -80°C until use. Isolation of total RNA was performed using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. The concentration and purity of the RNA samples was determined by UV spectroscopy.

For the reverse transcription (RT), 0.5 μg of total RNA was annealed to 100 ng random hexamers in a total volume of 12 μl. RT reactions were carried out in duplicate for all experimental samples, and in triplicate for the standard curve. Samples were heat denatured at 75°C for 3 min and quick-chilled on ice to minimize secondary structure present in the RNA. SuperScriptII RNase H Reverse Transcriptase (Invitrogen, Carlsbad, CA) was added in addition to 5x RT Buffer provided with the enzyme, 10 mM DTT, and 0.5 mM dNTP mix to bring the total reaction volume to 20 μl. Reactions were incubated for 1 h at 42°C and heat deactivated for 15 min at 70°C. Samples were diluted to 100 μl with RNase-free water (Invitrogen, Carlsbad, CA) and stored at -80°C until further use. Primer sets were designed to span an intron to avoid amplification from genomic DNA contamination. A BLASTN search was performed against GenBank to evaluate whether the primers were unique to the gene of interest. To avoid amplification from genomic DNA contamination, primer sets were designed to span an intron/exon junction. Sequences are as follows: rPer1 (Forward: AGGAGGCCCCGGAAGTAGT; Reverse: AGCCTGAAAGTGCATCCTGATT); rPer2 (Forward: GACGGGTCGAGCAAAGGA; Reverse: GGGAAAAGTCCACATATCC ATTCA); rBmal1 (Forward: TCTATCCGATGACGAACTGAA; Reverse: CCCTCGGTCACATCCTACAG) (Fig 1A).


Fig 1. At CT 10, melatonin induces of Per1 and Per2 transcription by 120 min.

A) qPCR amplification products migrate at the predicted size and are distinguishable on an 8% polyacrylamide gel stained with ethidium bromide (Per1 = 113 bp, Per2 = 90 bp, BMAL1 = 79 bp). B) Melatonin has no significant effect on the expression levels of Per1, Per2, or Bmal1 mRNA 30 min following the initiation of treatment (p ≥ 0.05, Student’s T Test). C) Melatonin treatment significantly increases Per1 and Per2, but not Bmal1, transcripts, at 120 min. Data are shown as percent change of relative mRNA levels compared to control ± SEM, n = 3-4/condition. ***p ≤ 0.001 (Per1), *p ≤ 0.05 (Per2), p ≥ 0.05 (Bmal1), Student’s T-test.

All qPCR reactions were carried out in triplicate (BioRad iCycler iQ) with 12.5 μl SYBR Green® Master Mix (Biorad, Hercules, CA), forward and reverse primers (final concentrations 300 nM (rPer1), 600 nM (rPer2), 300 nM (Bmal1)), 5 μl of diluted RT reaction, and RNase-free water to a final reaction volume of 25 μl. The initial denaturation was carried out at 95°C for 10 min, followed by 50 cycles of 50 sec at 95°C and 45 sec at 60°C. The qPCR results are represented as Ct values, or the cycle at which an arbitrary fluorescence threshold was reached. The threshold value was placed such that it was in the exponential portion of the amplification plot for all of the products being generated and was held constant for all runs. A heat disassociation curve was performed at the end of every run to determine that all signals were from an amplicon with the correct disassociation temperature. Negative controls included qPCR conditions that were the same apart from samples that (1) lacked RNA, or (2) lacked the reverse transcriptase enzyme during the RT reaction. Negative controls failed to cross threshold, indicating that the samples were free from amplification from genomic contamination.

A standard curve was generated for each primer set by performing serial dilutions of RNA and plotting the resultant Ct values against the log2 of the concentration. The slope, y-intercept, and r2 value of the standard curve was determined for each primer set. These values were used to determine the relative mRNA expression level for each experimental sample.


Spontaneous firing rates of individual neurons were assessed in vitro using the standard extracellular single-unit recording technique [27,28]. The mean firing rate for individual cells was determined over a 4-min period, and grouped into 2-h running averages with 15-min time lags. Average firing rate was plotted versus the circadian time of recorded activity. The time-of-peak for each experiment was determined from the plot of 2-h running averages for the highest firing rate. Phase shifts were assessed by comparing the mean time-of-peak for treatment groups to vehicle-treated controls. A single peak in spontaneous firing rate of SCN neurons in vitro has been described previously [18,29,30,31]. A subset of the recordings were performed with the experimenter blind to the treatment conditions.

Data analysis and statistics

All qPCR data were plotted as percent change of relative mRNA levels (± SEM) of experimental samples compared to controls (± SEM) that have been set to 100%. Statistical analyses were performed on the averages using a 1- or 2-way analysis of variance (ANOVA), with sample sizes ranging from 3–4 for each treatment. For extracellular recording of SCN neuronal activity, data were plotted as mean firing rate versus circadian time of recorded activity. Statistical analyses were performed on the average time-of-peak firing rate of experimental slices versus controls using a 1-way ANOVA. Sample sizes were 3–4 for each treatment.


Per1 and Per2, but not Bmal1, transcripts increase with melatonin at dusk

To test the hypothesis that clock resetting by melatonin is mediated by changes in the expression of core genes involved in circadian rhythm generation, we evaluated levels of Per1, Per2 and Bmal1 transcripts at CT 10. Assessment of relative levels was made by qPCR. Melatonin application (1 nM, 10 min) to the SCN at subjective dusk (CT 10) had no significant effect on Per1, Per2, or Bmal1 mRNA 30 min post-treatment (p ≥ 0.05, n = 3, 2-way ANOVA) (Fig 1B). However, melatonin significantly increased Per1 and Per2 mRNA compared to controls after 120 min (p ≤ 0.001 (Per1), p ≤ 0.05 (Per2), p ≥ 0.05 (Bmal1), n = 3, Student’s T-test) (Fig 1C).

Melatonin has no effect on Per1 or Per2 transcripts during the day, but Bmal 1 is reduced

At mid-subjective day (CT 6), when melatonin has no impact on the timing of SCN rhythms in the rat [5], melatonin application had no significant effect on the expression levels of Per1, Per2, or Bmal1 mRNA compared to vehicle-treated controls at 30 min or the expression levels of Per1 or Per2 mRNA compared to vehicle-treated controls at 120 min following treatment (p ≥ 0.05, n = 8–9, Student’s T-test) (Fig 2). Only Bmal1 mRNA levels was significantly reduced compared to vehicle-treated controls at 120 min following treatment at CT 6 (p = 0.047).


Fig 2. At CT 6, melatonin does not change the levels of Per1 and Per2 transcripts, although Bmal1 is reduced at 120 min.

Melatonin applied at CT 6 has no significant effect on the expression levels of Per 1, Per2, or Bmal1 mRNA after 30 min (A). After 120 min (B), only Bmal1 mRNA significantly decreases following initiation of melatonin treatment at CT 6. Data are shown as percent change of relative mRNA levels compared to control ± SEM, n = 3–9 /condition, p ≥ 0.05 (Per 1, Per 2), *p ≤ 0.05 (Bmal1), Student’s T-test.

PKC activation is necessary for melatonin-induced changes in Per1 and Per2 expression at dusk

To test the hypothesis that PKC is a necessary signaling element leading to a change in clock gene expression by melatonin, the PKC inhibitor, chelerythrine chloride (CC), was incubated with SCN slices 20 min before melatonin or EBSS (control) treatment at CT 10. When SCN slices were pre-treated with 0.25 mM CC prior to melatonin, the increase in Per1 and Per2 mRNA was abolished (p ≤ 0.01 (Per1), p ≤ 0.01 (Per2), 1-way ANOVA) (Fig 3). These results support a role for PKC in the transduction of the melatonin signal to affect clock gene expression in the SCN.


Fig 3. The PKC inhibitor, chelerythrine chloride, blocks the increase of Per1 and Per2 mRNA induced by melatonin applied at CT 10.

Pre-treatment with 0.25 mM of the PKC inhibitor, chelerythrine chloride, blocks the melatonin-induced increase in Per1(A) and Per2(B) transcripts after 120 min. Data are shown as percent change of relative mRNA levels compared to control ± SEM, n = 3/condition (** p ≤ 0.01, *p ≤ 0.05, 1-way ANOVA, Tukey’s post-hoc analysis). Controls were exposed to sham treatment lacking MEL. MEL = melatonin. CC = chelerythrine chloride.

Increase in Per1 and Per2 mRNA is required for melatonin to advance neuronal activity rhythms at CT 10

To determine whether the rise in Per1 and/or Per2 mRNA is required for melatonin to induce a phase advance in SCN neuronal activity rhythms, brain slices were pre-treated with αODN targeted to either Per1 or Per2 in the absence or presence of melatonin. αODNs act as specific decoys, providing excess, specific binding sites that out-compete native sites for transcription factors. Their use for evaluating the induction of E-box-regulated transcription in the SCN circadian clock is well established [21]. Thus, if E-box-mediated transcriptional activation is required for melatonin-induces phase-shifts, then pre-treatment of SCN slices with an E-box αODN should prevent an increase in Per1 and Per2 mRNAs and block a melatonin-induced phase advance in neuronal activity rhythms. A 2-h pulse of αODN (10 μM) from CT 8–10 was sufficient to induce a 45% decrease in Per1 mRNA, and 60% decrease in Per2 mRNA, as assayed by RT-PCR (Fig 4). This knockdown is consistent with previous reports using αODN to attenuate Per transcripts in the SCN [22,24]. Thus, if melatonin increases Per1 and Per2 transcripts to result in a downstream phase-shift, pre-treatment of SCN slices with αODN should prevent an increase in Per1 and Per2 mRNAs and block melatonin-induced phase advances in neuronal activity rhythms as previously reported [5,6].


Fig 4. Per1 and Per2 αODN attenuate the expression of corresponding transcripts in the SCN.

2-h incubation of SCN slices with αODN results in a 45% decrease in Per1 transcripts (A) and a 60% decrease in Per2 transcripts (B) 4 h after initiation of treatment with the corresponding αODN. No change in GAPDH mRNA was evident following either treatment, which was used as a normalization control.

The ensemble SCN firing rate in the rat SCN peaked at CT 6.38 ± 0.13 (n = 4) in control slices (Fig 5A). Melatonin treatment at CT 10 induced a 3.6-h phase advance in the time-of-peak neuronal activity compared to controls (Fig 5B, mean time-of-peak = CT 2.75 ± 0.10, n = 4, p ≤ 0.001, ANOVA). Per1 αODN alone from CT 8–10 had no significant effect on clock timing (Fig 5C, mean time-of-peak = CT 6.42 ± 0.22, n = 3, p ≥ 0.05, ANOVA), but pre-treatment of the SCN with Per1 αODN inhibited the advance in neuronal rhythms induced by melatonin (Fig 5D, mean time-of-peak = CT 6.38 ± 0.30, n = 4, p ≥ 0.05, ANOVA). To control for non-specific effects of the ODN treatment, brain slices were incubated with Per1 missense ODN for 2 h before melatonin application. Per1 missense ODN had no effect alone (Fig 5E, mean time-of-peak = CT 6.75 ± 0.20, n = 4, p ≥ 0.05, ANOVA) or on melatonin-induced advances in neuronal activity in the SCN (Fig 5F, mean time-of-peak = CT 2.83 ± 0.44, n = 3, p ≤ 0.001, ANOVA).


Fig 5. Per1 is required for melatonin to alter the phase of SCN neuronal activity rhythms at CT 10.

A) The spontaneous electrical activity rhythm in SCN brain slices peaks at CT 6.38 ± 0.13 in controls. The dotted line indicates the mean time-of-peak for untreated slices. Long, vertical boxes represent subjective night, CT 12–14. B) At CT 10, MEL (1 nM, 10 min) advances the electrical activity rhythm by 3.6 h ± 0.10 (n = 3). Arrow = time of melatonin treatment. C)Per1 αODN application from CT 8–10 has no significant effect on the time-of-peak electrical activity (n = 3). Small box = duration of ODN exposure. D) The MEL-induced phase advance is completely blocked by Per1 αODN (n = 3). E)Per1 missense ODN has no effect on the MEL-induced advance in time-of-peak electrical activity (n = 3). F)Per1 missense ODN does not block the MEL-induced phase advance at CT 10. G) Summary of the effects of Per1 ODN on MEL-induced phase advances at CT 10. **indicates statistically significant difference compared to controls (p ≤ 0.001) as determined by 1-way ANOVA with Tukey’s post-hoc analysis.

Likewise, a 2-h exposure from CT 8–10 to Per2 αODN alone had no significant effect on SCN clock timing (Fig 6C, mean time-of-peak = CT 6.0 ± 0.23, n = 4, p ≥ 0.05, ANOVA), but pre-treatment with Per2 αODN prior to upon melatonin exposure at CT 10 inhibited the phase advance in spontaneous neuronal activity (Fig 6D, mean time-of-peak = CT 6.31 ± 0.12, n = 4, p ≥ 0.05, ANOVA). Missense Per2 ODN had no effect alone (Fig 6E, mean time-of-peak = CT 6.5 ± 0.29, n = 3, p ≥ 0.05, ANOVA) nor on the melatonin-induced phase advance (Fig 6F, mean time-of-peak = CT 2.92 ± 0.17, n = 3, p ≤ 0.001, ANOVA). These results suggest that melatonin-induced increases at CT 10 in both Per1 and Per2 mRNA are necessary to elicit a phase advance in the circadian rhythm of neuronal firing in the rat SCN.


Fig 6. Per2 is required for melatonin to phase-shift SCN neuronal activity rhythms at CT 10.

A) The spontaneous electrical activity rhythm in SCN brain slices peaks at CT 6.38 ± 0.13 in control SCN (n = 3). B) At CT 10, MEL (1 nM, 10 min) advances the electrical activity rhythm by 3.6 h ± 0.10 (n = 3). C)Per2 αODN application from CT 8–10 has no effect on the mean time-of-peak electrical activity (n = 3). Small box = duration of ODN exposure. D) The MEL-induced phase advance is blocked completely by pre-incubation from CT 8–10 with Per2 αODN (n = 3). E) Pre-incubation with Per2 missense ODN has no effect on the MEL-induced advance in time-of-peak electrical activity (n = 3). F) Pre-incubation with Per2 missense ODN has no effect on the MEL-induced phase advance at CT 10 (n = 3). G) Summary of the effects of Per2 αODN pre-incubations on MEL-induced phase advances at CT 10. **indicates statistically significant differences (p ≤ 0.001) as determined by 1-way ANOVA with Tukey’s post-hoc analysis. Symbols as in Fig 5.

Decoy ODN blocks binding at E-box sequences in SCN 2.2 cells

The E-box decoy is a double-stranded DNA sequence designed to bind to saturate transcription factors that would otherwise bind to E-box sites in the promoters of target genes, thereby preventing their action. To determine whether the E-box decoy could sequester endogenous E-box-binding factors, E-box decoy ODN (1 μM) was transfected into an immortalized SCN cell line (SCN 2.2) and subsequent DNA-protein interactions were assessed by electrophoretic mobility assay. E-box decoy ODN, but not missense ODN, effectively prevented binding of endogenous transcription factors to E-box sites in SCN 2.2 cells for up to 24 h (Fig 7).


Fig 7. E-box decoy blocks binding at E-box sites in SCN 2.2 cells.

Electromobility shift assay of an E-box probe incubated with nuclear extracts of SCN 2.2 cells transfected with 1 μM E-box decoy or missense ODN. Media lane indicates non-transfected control. Arrow = retarded mobility of the E-box probe. This DNA-protein interaction is absent in SCN 2.2 cells transfected with the E-box decoy up to 24 h (n = 3).

E-box sequences mediate Per1 and Per2 expression changes by melatonin

To examine the necessity of the E-box promoter motif for the changes in clock gene expression induced by melatonin, E-box decoy ODN (1 μM) was incubated with SCN slices for 2 h before exposure at CT 10 to melatonin or EBSS (control) treatment. Decoy ODN effectively blocked the increase in Per1 and Per2 mRNA at 120 min following melatonin application at CT 10 (p ≤ 0.01 (Per1), p ≤ 0.01 (Per2), 1-way ANOVA) (Fig 8).


Fig 8. Melatonin-induced increases in Per1 and Per2 mRNAs are blocked by E-box decoy ODN.

Pre-treatment of SCN slices with E-box decoy ODN (1 μM), blocks the melatonin-induced increase in Per1(A) and Per2(B) transcripts after 120 min. qPCR data are shown as percent change of relative mRNA levels compared to control ± SEM, n = 3/condition (** p ≤ 0.01, *p ≤ 0.05, 1-way ANOVA, Tukey’s post-hoc analysis). MEL = melatonin.

E-box-mediated transcription is necessary for melatonin to induce a phase advance in neuronal activity rhythms at CT 10

To assess the role of E-box regulatory elements in the melatonin-induced phase advance in SCN firing rate rhythms, SCN brain slices were pre-treated with E-box decoy or missense ODN from CT 8–10 in the presence or absence of melatonin. The circadian rhythm in SCN firing rate peaked at CT 6.38 ± 0.13 (n = 4) in control slices (Fig 9A). Bilateral administration of melatonin to the SCN in brain slices at CT 10 induced a 3.6-h phase advance in the peak of neuronal activity compared to controls (Fig 9B, mean time-of-peak = CT 2.75 ± 0.10, n = 4, p ≤ 0.001, ANOVA). E-box decoy ODN (1 μM) alone had no significant effect on clock timing (Fig 9C, mean time-of-peak = CT 6.92 ± 0.3, n = 3, p ≥ 0.05, ANOVA), but abolished the advance in neuronal rhythms induced by melatonin (Fig 9D, mean time-of-peak = CT 6.75 ± 0.42, n = 4, p ≥ 0.05, ANOVA). After similar pre-treatment with missense ODN alone (CT 8–10), melatonin application at CT 10 had no effect on clock timing (Fig 9E, mean time-of-peak = CT 6.75 ± 0.14, n = 3, p ≥ 0.05, ANOVA) nor on the melatonin-induced phase advance (Fig 9F, mean time-of-peak = CT 3.5 ± 0.14, n = 3, p ≤ 0.001, ANOVA).


Fig 9. E-box promoter motif is required for melatonin to shift SCN neuronal activity rhythms at CT 10.

A) The spontaneous electrical activity rhythm in SCN brain slices peaks at CT 6.38 ± 0.13 in controls (n = 3). The dotted line indicates the mean time-of-peak for untreated slices. Large, vertical boxes represent subjective night, CT 12–14. B) At CT 10, MEL (1 nM, 10 min) advances the electrical activity rhythm by 3.6 h ± 0.10 (n = 3). Arrow = time of melatonin treatment. C) E-box decoy ODN has no significant effect on the time-of-peak electrical activity (n = 3). Small box = duration of ODN exposure. D) The MEL-induced phase advance is blocked by the E-box decoy ODN (n = 3). E) Missense ODN has no effect on the MEL-induced advance in time-of-peak electrical activity (n = 3). F) Missense ODN does not block the MEL-induced phase advance at CT 10 (n = 3). G) Summary of the effects of ODN on MEL-induced phase advances at CT 10. **indicates statistically significant difference compared to controls (p ≤ 0.001) as determined by 1-way ANOVA with Tukey’s post- hoc analysis.


These studies investigated the hypothesis that melatonin alters SCN clock phasing at dusk via the regulation of core genes that comprise the molecular circadian clock. Melatonin entrains circadian rhythms of wheel-running activity after a sequence of daily injections in vivo [32,33,34,35]. Single, brief applications of melatonin to the SCN in a brain slice in the SCN during late subjective day and late subjective night, but not during the day advance the peak of neural activity rhythms [5,36]. Thus, we predicted that melatonin application at CT 10, but not at CT 6, would alter the expression of clock genes. At CT 10, melatonin significantly increased the expression of Per1 and Per2, but not Bmal1, an effect that was absent after treatment at CT 6 (Figs 1C and 2). Moreover, phase-resetting effects of melatonin at CT 10 were inhibited by αODN targeted to Per1 and Per2. Changes in Per1 and Per2 expression are key for light/glutamate to modulate clock timing during the night [14,23]. These findings extend data on light-induced changes in Per1 and Per2 to a nonphotic zeitgeber, melatonin, and suggest that the regulation of these clock gene transcripts is required for clock resetting by diverse regulatory cues.

Light in the early night transiently increases Per1 transcripts within 30–60 min; levels return to baseline after 3 h [37,38,39]. Per2 mRNA is induced more slowly, peaking within 2–3 h, followed by a sustained increase for ~6 h [38,39,40]. In the late night, light induces Per1 mRNA that peaks after 60 min; however, there is no significant effect on Per2 transcripts at this time [16,39]. The present study demonstrates sensitivity of Per1 and Per2 transcriptional activation to melatonin as well, albeit with a slower time course for Per1 induction by melatonin at CT 10 (Fig 1C). Other nonphotic stimuli, which act in daytime to adjust SCN phasing, induce a decline in Per 1 and Per 2 transcripts [41,42,43,44]. Thus, melatonin engages the molecular clock by a mechanism that shares transcriptional targets with light stimulation at night, but is distinct from other nonphotic stimuli.

In the unperturbed SCN, Per1 levels peak early in the subjective day (CT 4–6), and are relatively low at subjective dusk (CT 10). Non-photic resetting cues that alter clock timing during the day while Per1 levels are naturally high, induce a decline in Per1. However, the induction of Per1 mRNA by light/glutamate as well as by melatonin suggests that Per1 is likely to be a gene that is turned on by exposure to a range of phase shifting stimuli at times when Per1 mRNA is low, from late day through the night. In this case, melatonin is being applied to the SCN at subjective dusk, a time when Per1 transcript levels are low.

The results described here differ from those reported by Poirel et al. [45] showing no effect of melatonin on clock gene expression in the SCN within 24-h of treatment. Differences in experimental design, including methods and conditions of melatonin administration, may account for the differing results. First, Poirel et al. [45] used a single subcutaneous injection of melatonin into the rat in vivo at CT 11.5; effects of circadian phase were not examined. In contrast, we applied melatonin directly to the SCN in brain slices in vitro at CT 10 and demonstrated that this induces phase-resetting of neuronal activity rhythms. Second, previous reports have shown that three consecutive days of single injections i.p. are necessary to obtain phase-shifting in mice [46]. In humans, four oral doses of melatonin have been used to generate a phase-response curve of the dim-light melatonin onset (DLMO) to melatonin [47]. Additionally, three consecutive days of melatonin administration at the onset of dark in the C3H/HeN mouse facilitated the rate of re-entrainment following an advance in the LD cycle [48]. In a model of seasonal depression, repeated melatonin i.p. administration at 6 hr into the day of mice exhibiting depressive behavior on a short-day lighting cycle increased the amplitude of clock gene expression, but did not change the phase [49]. Based on the studies cited above, a single melatonin injection in vivo is unlikely to have reset the circadian clock and thus unlikely to result in corresponding changes in clock gene expression.

E-box cis-regulatory enhancer sequences are DNA elements critical to the molecular feedback loop that underlies circadian rhythmicity, in that they are necessary for transcription initiation of Per1 and Per2 [9,50]. In this study, an E-box-specific ODN was used to probe the involvement of E-box promoter elements in melatonin-induced phase resetting. E-box ODN decoys, but not missense ODN, prevented endogenous E-box-binding factors from binding to E-box sequences in the DNA of SCN2.2 cells (Fig 7). This indicates that E-box ODNs can penetrate cells, and can effectively block E-box-specific transcription factors from binding to E-box sequences and activating downstream gene expression. E-box ODN decoys acts as global E-box inhibitors, outcompeting endogenous E-boxes both due to their binding efficiency and by far exceeding the numbers of intrinsic binding sites. In the case of both Per 1 and Per 2, the E-box decoys are competing for the same BMAL/CLOCK dimer pool. Thus, the numbers of available BMAL/CLOCK dimers available to bind to all E-box promoter elements is significantly diminished, and all-E-box-mediated transcription inhibited [25]. Importantly, the effect of the E-box ODN decoy is on the transcription factors themselves, not to the specific E-box sequences.of Per 1 vs. Per 2 promoters.

Pre-treatment of SCN brain slices with E-box decoy, but not missense, ODN effectively blocked melatonin-induced advances in neuronal activity, but had no effect on clock phase when applied to the SCN alone (Fig 9). Similarly, E-box decoy prevented the melatonin-induced changes in Per1 and Per2 expression (Fig 8). These results implicate the E-box promoter element in generating shifts in the SCN clock by melatonin at subjective dusk. We are unaware of prior evidence linking the E-box promoter motif to the melatonin-induced phase advance in SCN neuronal activity rhythm. However, we identified the E-box element as a necessary target for clock resetting in the glutamate signaling pathway in the SCN [26]. This suggest that melatonin and glutamate signals both target activation of Period gene expression via binding of transcription factors to E-boxes for circadian clock resetting.

There are several mechanisms by which melatonin may affect E-box-dependent transcription in the SCN. The melatonin signal may positively regulate gene transcription by facilitating the binding of CLOCK/BMAL1 heterodimers to E-box containing promoters and recruiting transcription factors [9,51]. Alternatively, melatonin may activate already-bound CLOCK/BMAL1 complexes. This could occur via recruitment of co-activators, which may trigger the intrinsic histone acetyltransferase (HAT) activity of CLOCK [52], thereby making the DNA more accessible to transcriptional machinery. Either scenario would promote the initiation of Per1 and Per2 transcription.

Advances in our understanding of the molecular clockwork mechanism include a role for post-translational modifications affecting clock protein function [53]. This raises the possibility that the melatonin signal may influence the transactivation potential of DNA binding proteins via protein kinases. There is evidence that mammalian CLOCK is phosphorylated and activated via a Ca2+-dependent PKC pathway [54].

Alternatively, melatonin signaling components may affect Per1 and Per2 expression by relieving transcriptional inhibition at E-box promoters. There is evidence for this type of regulation, whereby the DEC (differentially expressed in chondrocytes) transcription factors, DEC1 and DEC2, repress CLOCK/BMAL1-induced transcriptional activation of the mouse Per1 gene [55]. Perhaps melatonin facilitates the de-repression of CLOCK/BMAL1 at the level of DEC1 and/or DEC2, thereby inducing Per1 and Per2 gene expression. However, there is currently no evidence linking melatonin and activation of DEC proteins.

We have examined the effect of the E-box decoy ODN alone and in combination with melatonin in the rat hypothalamic brain slice in vitro, and conclude that the E-box promoter motif is required for transmitting signals of change by melatonin to the circadian clock at CT 10 in vitro. The contribution of CLOCK/BMAL1-induced activation of Per1 and Per2 expression to alter clock timing by melatonin is unclear at this time, but warrants further investigation. These data support the notion that the regulation of clock genes by upstream activating sequences is required for clock resetting not only by light, but also by other regulatory stimuli, including the pineal hormone melatonin.

Melatonin alters clock phase by activating PKC [5]. A specific inhibitor of PKC, chelerythrine chloride (CC), blocked the changes induced by melatonin in Per1 and Per2 transcripts (Fig 3). These findings place melatonin, MT2 receptor activation, PKC activation, and downstream induction of Per1 and Per2 mRNA via E-boxes in a signaling cascade mediating phase advances at CT 10. We previously have shown that melatonin also alters clock phasing at CT22, subjective dawn in the SCN. As during subjective dusk at CT 10, PKC signaling is necessary for the effect of melatonin on SCN phase at dawn [5]. The effect of melatonin on clock genes at this important circadian time warrants further investigation.

Investigations into the molecular nature of the mammalian timing system have defined a general framework for central clock mechanisms, although understanding is still incomplete. The mammalian circadian clock is extraordinarily complex dynamic system, responding to a diverse and growing list of phase-shifting stimuli. Each stimulus potentially encodes a distinct time-of-day signature that adjusts the SCN oscillatory machinery so as to synchronize with day and night. Specific time-of-day effects of melatonin on Per1 and Per2 transcriptional activation that wax and wane are consistent with the dynamic nature of the timekeeping mechanism. The changes in Per1 and Per 2 expression induced by melatonin, a non-photic stimulus, during the approach tonight support a transcriptional induction of change that shares some components with mediators of effects of light on the SCN clock several hours later, during the night.


The authors thank Karen Weis for help with tissue collection, Ghazal Naseri Kouzehgarani for statistical consultation, Deavid Earnest for the gift of the original SCN2.2 cell line, and Ann Benefiel and Maureen Holtz for preparing the manuscript. Support from The National Heart, Lung and Blood Institute (HL086870) and the National Science Foundation (IOS 1354913) is gratefully acknowledged.

Author Contributions

Conceived and designed the experiments: PCK MUG. Performed the experiments: PCK JWM. Analyzed the data: PCK JWM MUG. Contributed reagents/materials/analysis tools: PCK JWM MUG. Wrote the paper: PCK JWM MUG.


  1. 1. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI (2003) Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 8: d1093–1108. pmid:12957828
  2. 2. Vanecek J, Pavlik A, Illnerova H (1987) Hypothalamic melatonin receptor sites revealed by autoradiography. Brain Res 435: 359–362. pmid:2827856
  3. 3. Weaver DR, Rivkees SA, Reppert SM (1989) Localization and characterization of melatonin receptors in rodent brain by in vitro autoradiography. J Neurosci 9: 2581–2590. pmid:2545841
  4. 4. Gillette MU, McArthur AJ (1996) Circadian actions of melatonin at the suprachiasmatic nucleus. Behav Brain Res 73: 135–139. pmid:8788491
  5. 5. McArthur AJ, Hunt AE, Gillette MU (1997) Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: activation of protein kinase C at dusk and dawn. Endocrinology 138: 627–634. pmid:9002996
  6. 6. Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML (2001) Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol 280: C110–118. pmid:11121382
  7. 7. Pfeffer M, Rauch A, Korf HW, von Gall C (2012) The endogenous melatonin (MT) signal facilitates reentrainment of the circadian system to light-induced phase advances by acting upon MT2 receptors. Chronobiol Int 29: 415–429. pmid:22489607
  8. 8. Bunger MK, Wilsbacher LD, Moran SM, Clendenin C, Radcliffe LA, Hogenesch JB, et al. (2000) Mop3 is an essential component of the master circadian pacemaker in mammals. Cell 103: 1009–1017. pmid:11163178
  9. 9. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, et al. (1998) Role of the CLOCK protein in the mammalian circadian mechanism. Science 280: 1564–1569. pmid:9616112
  10. 10. Jin X, Shearman LP, Weaver DR, Zylka MJ, de Vries GJ, Reppert SM (1999) A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell 96: 57–68. pmid:9989497
  11. 11. Emery P, Reppert SM (2004) A rhythmic Ror. Neuron 43: 443–446. pmid:15312644
  12. 12. Lowrey PL, Takahashi JS (2004) Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet 5: 407–441. pmid:15485355
  13. 13. Kume K, Zylka MJ, Sriram S, Shearman LP, Weaver DR, Jin X, et al. (1999) mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell 98: 193–205. pmid:10428031
  14. 14. Akiyama M, Kouzu Y, Takahashi S, Wakamatsu H, Moriya T, Maetani M, et al. (1999) Inhibition of light- or glutamate-induced mPer1 expression represses the phase shifts into the mouse circadian locomotor and suprachiasmatic firing rhythms. J Neurosci 19: 1115–1121. pmid:9920673
  15. 15. Tischkau SA, Mitchell JW, Tyan SH, Buchanan GF, Gillette MU (2003) Ca2+/cAMP response element-binding protein (CREB)-dependent activation of Per1 is required for light-induced signaling in the suprachiasmatic nucleus circadian clock. J Biol Chem 278: 718–723. pmid:12409294
  16. 16. Albrecht U, Sun ZS, Eichele G, Lee CC (1997) A differential response of two putative mammalian circadian regulators, mper1 and mper2, to light. Cell 91: 1055–1064. pmid:9428527
  17. 17. Tischkau SA, Mitchell JW, Pace LA, Barnes JW, Barnes JA, Gillette MU (2004) Protein kinase G type II is required for night-to-day progression of the mammalian circadian clock. Neuron 43: 539–549. pmid:15312652
  18. 18. Gillette MU (1986) The suprachiasmatic nuclei: circadian phase-shifts induced at the time of hypothalamic slice preparation are preserved in vitro. Brain Res 379: 176–181. pmid:3742212
  19. 19. Hatton GI, Doran AD, Salm AK, Tweedle CD (1980) Brain slice preparation: hypothalamus. Brain Res Bull 5: 405–414. pmid:7407637
  20. 20. Dobler G, Gniel D, Petermann R, Pfeffer M (2012) Epidemiology and distribution of tick-borne encephalitis. Wien Med Wochenschr.
  21. 21. Hurst WJ (2001) Investigation of the SCN 2.2 cell line as a model of the central mammalian circadian pacemaker. Thesis (Ph.D.)—University of Illinois at Urbana-Champaign.
  22. 22. Sugiyama T, Yoshioka T, Ikeda M (2004) mPer2 antisense oligonucleotides inhibit mPER2 expression but not circadian rhythms of physiological activity in cultured suprachiasmatic nucleus neurons. Biochem Biophys Res Commun 323: 479–483. pmid:15369776
  23. 23. Wakamatsu H, Takahashi S, Moriya T, Inouye ST, Okamura H, Akiyama M, et al. (2001) Additive effect of mPer1 and mPer2 antisense oligonucleotides on light-induced phase shift. Neuroreport 12: 127–131. pmid:11201072
  24. 24. Hamada T, Antle MC, Silver R (2004) The role of Period1 in non-photic resetting of the hamster circadian pacemaker in the suprachiasmatic nucleus. Neurosci Lett 362: 87–90. pmid:15193760
  25. 25. Tischkau SA, Gillette MU (2005) Oligodeoxynucleotide methods for analyzing the circadian clock in the suprachiasmatic nucleus. Methods Enzymol 393: 593–610. pmid:15817314
  26. 26. Hurst WJ, Mitchell JW, Gillette MU (2002) Synchronization and phase-resetting by glutamate of an immortalized SCN cell line. Biochemical and biophysical research communications 298: 133–143. pmid:12379231
  27. 27. Prosser RA, Gillette MU (1989) The mammalian circadian clock in the suprachiasmatic nuclei is reset in vitro by cAMP. J Neurosci 9: 1073–1081. pmid:2538580
  28. 28. Prosser RA, McArthur AJ, Gillette MU (1989) cGMP induces phase shifts of a mammalian circadian pacemaker at night, in antiphase to cAMP effects. Proc Natl Acad Sci U S A 86: 6812–6815. pmid:2549549
  29. 29. Green DJ, Gillette R (1982) Circadian rhythm of firing rate recorded from single cells in the rat suprachiasmatic brain slice. Brain Res 245: 198–200. pmid:6889453
  30. 30. Groos G, Hendriks J (1982) Circadian rhythms in electrical discharge of rat suprachiasmatic neurones recorded in vitro. Neurosci Lett 34: 283–288. pmid:6298675
  31. 31. Shibata S, Oomura Y, Kita H, Hattori K (1982) Circadian rhythmic changes of neuronal activity in the suprachiasmatic nucleus of the rat hypothalamic slice. Brain Res 247: 154–158. pmid:7127113
  32. 32. Cassone VM, Chesworth MJ, Armstrong SM (1986) Entrainment of rat circadian rhythms by daily injection of melatonin depends upon the hypothalamic suprachiasmatic nuclei. Physiol Behav 36: 1111–1121. pmid:3014578
  33. 33. Redman J, Armstrong S, Ng KT (1983) Free-running activity rhythms in the rat: entrainment by melatonin. Science 219: 1089–1091. pmid:6823571
  34. 34. Pitrosky B, Kirsch R, Malan A, Mocaer E, Pevet P (1999) Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist. Am J Physiol 277: R812–828. pmid:10484499
  35. 35. Slotten HA, Pitrosky B, Pevet P (1999) Influence of the mode of daily melatonin administration on entrainment of rat circadian rhythms. J Biol Rhythms 14: 347–353. pmid:10511002
  36. 36. McArthur AJ, Gillette MU, Prosser RA (1991) Melatonin directly resets the rat suprachiasmatic circadian clock in vitro. Brain Res 565: 158–161. pmid:1773352
  37. 37. Shigeyoshi Y, Taguchi K, Yamamoto S, Takekida S, Yan L, Tei H, et al. (1997) Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript. Cell 91: 1043–1053. pmid:9428526
  38. 38. Shearman LP, Zylka MJ, Weaver DR, Kolakowski LF Jr., Reppert SM (1997) Two period homologs: circadian expression and photic regulation in the suprachiasmatic nuclei. Neuron 19: 1261–1269. pmid:9427249
  39. 39. Zylka MJ, Shearman LP, Weaver DR, Reppert SM (1998) Three period homologs in mammals: differential light responses in the suprachiasmatic circadian clock and oscillating transcripts outside of brain. Neuron 20: 1103–1110. pmid:9655499
  40. 40. Takumi T, Matsubara C, Shigeyoshi Y, Taguchi K, Yagita K, Maebayashi Y, et al. (1998) A new mammalian period gene predominantly expressed in the suprachiasmatic nucleus. Genes Cells 3: 167–176. pmid:9619629
  41. 41. Maywood ES, Mrosovsky N, Field MD, Hastings MH (1999) Rapid down-regulation of mammalian period genes during behavioral resetting of the circadian clock. Proc Natl Acad Sci U S A 96: 15211–15216. pmid:10611364
  42. 42. Mendoza JY, Dardente H, Escobar C, Pevet P, Challet E (2004) Dark pulse resetting of the suprachiasmatic clock in Syrian hamsters: behavioral phase-shifts and clock gene expression. Neuroscience 127: 529–537. pmid:15262341
  43. 43. Fukuhara C, Brewer JM, Dirden JC, Bittman EL, Tosini G, Harrington ME (2001) Neuropeptide Y rapidly reduces Period 1 and Period 2 mRNA levels in the hamster suprachiasmatic nucleus. Neurosci Lett 314: 119–122. pmid:11704298
  44. 44. Horikawa K, Yokota S, Fuji K, Akiyama M, Moriya T, Okamura H, et al. (2000) Nonphotic entrainment by 5-HT1A/7 receptor agonists accompanied by reduced Per1 and Per2 mRNA levels in the suprachiasmatic nuclei. J Neurosci 20: 5867–5873. pmid:10908630
  45. 45. Poirel VJ, Boggio V, Dardente H, Pevet P, Masson-Pevet M, Gauer F (2003) Contrary to other non-photic cues, acute melatonin injection does not induce immediate changes of clock gene mRNA expression in the rat suprachiasmatic nuclei. Neuroscience 120: 745–755. pmid:12895514
  46. 46. Benloucif S, Dubocovich ML (1996) Melatonin and light induce phase shifts of circadian activity rhythms in the C3H/HeN mouse. J Biol Rhythms 11: 113–125. pmid:8744239
  47. 47. Lewy AJ, Ahmed S, Jackson JM, Sack RL (1992) Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 9: 380–392. pmid:1394610
  48. 48. Dubocovich ML, Benloucif S, Masana MI (1996) Melatonin receptors in the mammalian suprachiasmatic nucleus. Behav Brain Res 73: 141–147. pmid:8788492
  49. 49. Nagy AD, Iwamoto A, Kawai M, Goda R, Matsuo H, Otsuka T, et al. (2015) Melatonin adjusts the expression pattern of clock genes in the suprachiasmatic nucleus and induces antidepressant-like effect in a mouse model of seasonal affective disorder. Chronobiology international 32: 447–457. pmid:25515595
  50. 50. Darlington TK, Wager-Smith K, Ceriani MF, Staknis D, Gekakis N, Steeves TD, et al. (1998) Closing the circadian loop: CLOCK-induced transcription of its own inhibitors per and tim. Science 280: 1599–1603. pmid:9616122
  51. 51. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, et al. (1997) Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 272: 8581–8593. pmid:9079689
  52. 52. Doi M, Hirayama J, Sassone-Corsi P (2006) Circadian regulator CLOCK is a histone acetyltransferase. Cell 125: 497–508. pmid:16678094
  53. 53. Gallego M, Virshup DM (2007) Post-translational modifications regulate the ticking of the circadian clock. Nat Rev Mol Cell Biol 8: 139–148. pmid:17245414
  54. 54. Shim HS, Kim H, Lee J, Son GH, Cho S, Oh TH, et al. (2007) Rapid activation of CLOCK by Ca2+-dependent protein kinase C mediates resetting of the mammalian circadian clock. EMBO Rep 8: 366–371. pmid:17347670
  55. 55. Honma S, Kawamoto T, Takagi Y, Fujimoto K, Sato F, Noshiro M, et al. (2002) Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature 419: 841–844. pmid:12397359
Check for updates via CrossMark

Subject Areas


For more information about PLOS Subject Areas, click here.

We want your feedback.Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

  • Melatonin 
  • Messenger RNA 
  • Gene expression 
  • Circadian rhythms 
  • DNA transcription 
  • Gene regulation 
  • Transcription factors 
  • Analysis of variance 



$scn(ELEMENT as element/string/array of ELEMENTs, CLASSNAME as string)


ELEMENTDOM ElementstringDOM Element Array

The element(s) to assign the class. Can be a single DOM element, an element ID specified as a string, or an array of DOM Element objects. If specifying the ID as a string, the ID corresponds to the value for the id HTML attribute for the element you wish to assign a style.


The class to assign to the element(s). Any existing classes for the element(s) will be overwritten with the specified class.


The $scn() function sets the class name of the passed-in element(s). This will overwrite any class names the already being using by the element(s). Contrast this with the $acn() function which adds the class name to the element.


/*Set the class name of the 'firstname' element.*/ $scn('firstname','formInput'); /*Set the class name of multiple elements. Any existing class names for the elements will be removed.*/ $scn(['firstname','lastname','address','city','state','zip'],'formInput');

An element can have more than one class name.

Use {dialog.object}.getPointer() to get the DOM element for a control.

See Also

Report an issue with this page

  1. Bait wrap mesh
  2. Mariner marine riviera beach
  3. Mt6737 database file
  4. Air max tortoise shell

Cycling with cAMP

The suprachiasmatic nucleus (SCN) is the main mammalian timekeeper: it coordinates circadian rhythms in gene expression throughout the body. The traditional description of its pacemaker activity includes an intracellular negative-feedback loop through which the products of the clock genes period (Per) and cryptochrome suppress their own expression in the SCN. However, recent studies indicated that this description is incomplete, and Hastings and colleagues have now identified cyclic AMP signalling as a major component of the central oscillator.

The authors showed that cAMP levels oscillate in a circadian fashion in tissue slices of mouse SCN. In addition, they observed circadian expression of a luciferase reporter gene that contained a cAMP-response element (CRE). These findings could indicate that cAMP expression is regulated by circadian pacemaker activity; however, further experiments suggested that cAMP is itself part of the pacemaker.

Using the activity of a luciferase reporter gene that was under the control of the Per promoter as a measure of circadian gene transcription, the authors showed that reducing cAMP levels dampened circadian transcription in SCN slices in a dose-dependent manner. Prolonged reduction of cAMP levels also caused the cycles of circadian transcription in individual cells in an SCN slice, which are normally synchronized, to become desynchronized. In addition, elevating cAMP concentrations acutely increased circadian gene expression, and prolonged cAMP elevation reduced its rhythmicity.

When cAMP levels were simultaneously elevated in different SCN slices by pharmacological treatment, the slices' transcription cycles were synchronized. This effect disappeared with sustained cAMP elevation, but if cAMP was subsequently reduced by washing out the drugs, the circadian transcription cycles resynchronized. This suggests that acute changes in cAMP signalling affect transcriptional oscillation. Finally, slowing cAMP synthesis slowed the oscillations of circadian transcription in SCN neurons. Together, these findings show that not only are cAMP levels regulated by the circadian pacemaker, they also influence the activity of the pacemaker, indicating that cAMP is an integral part of the central oscillator.

In vivo experiments showed that slowing cAMP synthesis lengthened the period of circadian transcription in peripheral tissues and lengthened circadian activity (wheel running) patterns, revealing that the actions of cAMP in the central pacemaker also influence peripheral cells.

The authors also investigated the downstream factors through which cAMP sustains circadian transcriptional rhythms. Blocking hyperpolarization-activated cyclic-nucleotide-gated K+ (HCN) channels and inhibiting the guanine nucleotide exchange factors EPAC1 and EPAC2 decreased circadian gene expression in the SCN, whereas inhibiting cAMP-dependent protein kinases had no effect. cAMP-induced activation of EpacPACs in turn activates CRE-binding proteins, which are transcription factors that bind to CRE sequences on Per genes.

Recent studies have shown that the intracellular signalling molecules Ca2+ and cyclic adenosine diphosphate-ribose are involved in circadian pacemaking in Drosophila melanogaster and plants, respectively. Together with this study, they provide increasing evidence that an interaction between intracellular signalling molecules and transcriptional feedback loops forms an evolutionarily conserved mechanism for timekeeping.



  1. 1

    O'Neill, J. S. et al. cAMP-dependent signaling as a core component of the mammalian circadian pacemaker. Science320, 949–953 (2008)

    CASArticle Google Scholar


  1. 2

    Herzog, E. D. Neurons and networks in daily rhythms. Nature Rev. Neurosci.8, 790–802 (2007)

    CASArticle Google Scholar

Download references

About this article

Cite this article

Welberg, L. Cycling with cAMP. Nat Rev Neurosci9, 503 (2008).

Download citation

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

IF PHONES and FOOD WERE PEOPLE - Relatable Situations with Candy Snacks and Phones by 123 GO! SCHOOL



Chemical compound

For organic derivatives, see Organic thiocyanates.

Thiocyanate (also known as rhodanide) is the anion [SCN]. It is the conjugate base of thiocyanic acid. Common derivatives include the colourless salts potassium thiocyanate and sodium thiocyanate. Mercury(II) thiocyanate was formerly used in pyrotechnics.

Thiocyanate is analogous to the cyanate ion, [OCN], wherein oxygen is replaced by sulfur. [SCN] is one of the pseudohalides, due to the similarity of its reactions to that of halide ions. Thiocyanate used to be known as rhodanide (from a Greek word for rose) because of the red colour of its complexes with iron. Thiocyanate is produced by the reaction of elemental sulfur or thiosulfate with cyanide:

8 CN + S8 → 8 SCN
CN + S
3 → SCN + SO2−

The second reaction is catalyzed by thiosulfate sulfurtransferase, a hepatic mitochondrial enzyme, and by other sulfur transferases, which together are responsible for around 80% of cyanide metabolism in the body.[2]

Biological chemistry of thiocyanate in medicine[edit]

Thiocyanate[3] is known to be an important part in the biosynthesis of hypothiocyanite by a lactoperoxidase.[4][5][6] Thus the complete absence of thiocyanate or reduced thiocyanate[7] in the human body, (e.g., cystic fibrosis) is damaging to the human host defense system.[8][9]

Thiocyanate is a potent competitive inhibitor of the thyroid sodium-iodide symporter.[10] Iodine is an essential component of thyroxine. Since thiocyanates will decrease iodide transport into the thyroid follicular cell, they will decrease the amount of thyroxine produced by the thyroid gland. As such, foodstuffs containing thiocyanate are best avoided by iodide deficient hypothyroid patients.[11]

In the early 20th century, thiocyanate was used in the treatment of hypertension, but it is no longer used because of associated toxicity.[12]Sodium nitroprusside, a metabolite of which is thiocyanate, is however still used for the treatment of a hypertensive emergency. Rhodanese catalyzes the reaction of sodium nitroprusside with thiosulfate to form the metabolite thiocyanate. Thiocyanate is also a metabolite of the detoxification of cyanides by Rhodanese.

Coordination chemistry[edit]

{\displaystyle {\ce {S=C=N^{\ominus }<->{^{\ominus }S}-C}}{\ce {#N}}}

Resonance structures of the thiocyanate ion

Thiocyanate shares its negative charge approximately equally between sulfur and nitrogen. As a consequence, thiocyanate can act as a nucleophile at either sulfur or nitrogen — it is an ambidentate ligand. [SCN] can also bridge two (M−SCN−M) or even three metals (>SCN− or −SCN<). Experimental evidence leads to the general conclusion that class A metals (hard acids) tend to form N-bonded thiocyanate complexes, whereas class B metals (soft acids) tend to form S-bonded thiocyanate complexes. Other factors, e.g. kinetics and solubility, are sometimes involved, and linkage isomerism can occur, for example [Co(NH3)5(NCS)]Cl2 and [Co(NH3)5(SCN)]Cl2.[14]It [SCN] is considered as a weak ligand. ([NCS] is a strong ligand)[15]

Test for iron(III) and cobalt(II)[edit]

The blood-red colored (up) complex [Fe(NCS)(H2O)5]2+ (left), indicates the presence of Fe3+ in solution.

If [SCN] is added to a solution with iron(III) ions, a blood-red solution forms mainly due to the formation of [Fe(SCN)(H2O)5]2+, i.e. pentaaqua(thiocyanato-N)iron(III). Lesser amounts of other hydrated compounds also form: e.g. Fe(SCN)3 and [Fe(SCN)4].[16]

Similarly, Co2+ gives a blue complex with thiocyanate.[17] Both the iron and cobalt complexes can be extracted into organic solvents like diethyl ether or amyl alcohol. This allows the determination of these ions even in strongly coloured solutions. The determination of Co(II) in the presence of Fe(III) is possible by adding KF to the solution, which forms uncoloured, very stable complexes with Fe(III), which no longer react with SCN.[citation needed]

Phospholipids or some detergents aid the transfer of thiocyanatoiron into chlorinated solvents like chloroform and can be determined in this fashion.[18]

See also[edit]



  1. ^International Union of Pure and Applied Chemistry (2014). Nomenclature of Organic Chemistry: IUPAC Recommendations and Preferred Names 2013. The Royal Society of Chemistry. pp. 784, 1069. doi:10.1039/9781849733069. ISBN .
  2. ^Abraham, Klaus; Buhrke, Thorsten; Lampen, Alfonso (24 February 2015). "Bioavailability of cyanide after consumption of a single meal of foods containing high levels of cyanogenic glycosides: a crossover study in humans". Archives of Toxicology. 90 (3): 559–574. doi:10.1007/s00204-015-1479-8. PMC 4754328. PMID 25708890.
  3. ^Pedemonte, N.; Caci, E.; Sondo, E.; Caputo, A.; Rhoden, K.; Pfeffer, U.; di Candia, M.; Bandettini, R.; Ravazzolo, R.; Zegarra-Moran, O.; Galietta, L. J. (2007). "Thiocyanate Transport in Resting and IL-4-Stimulated Human Bronchial Epithelial Cells: Role of Pendrin and Anion Channels". Journal of Immunology. 178 (8): 5144–5153. doi:10.4049/jimmunol.178.8.5144. PMID 17404297.
  4. ^Conner, G. E.; Wijkstrom-Frei, C.; Randell, S. H.; Fernandez, V. E.; Salathe, M. (2007). "The Lactoperoxidase System Links Anion Transport to Host Defense in Cystic Fibrosis". FEBS Letters. 581 (2): 271–278. doi:10.1016/j.febslet.2006.12.025. PMC 1851694. PMID 17204267.
  5. ^White, W. E.; Pruitt, K. M.; Mansson-Rahemtulla, B. (1983). "Peroxidase-Thiocyanate-Peroxide Antibacterial System Does not Damage DNA". Antimicrobial Agents and Chemotherapy. 23 (2): 267–272. doi:10.1128/aac.23.2.267. PMC 186035. PMID 6340603.
  6. ^Thomas, E. L.; Aune, T. M. (1978). "Lactoperoxidase, Peroxide, Thiocyanate Antimicrobial System: Correlation of Sulfhydryl Oxidation with Antimicrobial Action". Infection and Immunity. 20 (2): 456–463. doi:10.1128/IAI.20.2.456-463.1978. PMC 421877. PMID 352945.
  7. ^Minarowski, Ł.; Sands, D.; Minarowska, A.; Karwowska, A.; Sulewska, A.; Gacko, M.; Chyczewska, E. (2008). "Thiocyanate concentration in saliva of cystic fibrosis patients"(PDF). Folia Histochemica et Cytobiologica. 46 (2): 245–246. doi:10.2478/v10042-008-0037-0. PMID 18519245.[permanent dead link]
  8. ^Moskwa, P.; Lorentzen, D.; Excoffon, K. J.; Zabner, J.; McCray, P. B. Jr.; Nauseef, W. M.; Dupuy, C.; Bánfi, B. (2007). "A Novel Host Defense System of Airways is Defective in Cystic Fibrosis". American Journal of Respiratory and Critical Care Medicine. 175 (2): 174–183. doi:10.1164/rccm.200607-1029OC. PMC 2720149. PMID 17082494.
  9. ^Xu, Y.; Szép, S.; Lu, Z.; Szep; Lu (2009). "The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseases". Proceedings of the National Academy of Sciences of the United States of America. 106 (48): 20515–20519. Bibcode:2009PNAS..10620515X. doi:10.1073/pnas.0911412106. PMC 2777967. PMID 19918082.CS1 maint: multiple names: authors list (link)
  10. ^Braverman L. E.; He X.; Pino S.; et al. (2005). "The effect of perchlorate, thiocyanate, and nitrate on thyroid function in workers exposed to perchlorate long-term". J Clin Endocrinol Metab. 90 (2): 700–706. doi:10.1210/jc.2004-1821. PMID 15572417.
  11. ^"Hypothyroidism". University of Maryland Medical Center. Retrieved 3 December 2014.
  12. ^Warren F. Gorman; Emanuel Messinger; And Morris Herman (1949). "Toxicity of Thiocyanates Used in Treatment of Hypertension". Ann Intern Med. 30 (5): 1054–1059. doi:10.7326/0003-4819-30-5-1054. PMID 18126744.
  13. ^Palenik, Gus J.; Clark, George Raymond (1970). "Crystal and molecular structure of isothiocyanatothiocyanato-(1-diphenylphosphino-3-dimethylaminopropane)palladium(II)". Inorganic Chemistry. 9 (12): 2754–2760. doi:10.1021/ic50094a028. ISSN 0020-1669.
  14. ^Greenwood, p. 326
  15. ^"coordination compounds"(PDF).
  16. ^Greenwood, p. 1090
  17. ^Uri, N (1947-01-01). "The stability of the cobaltous thiocyanate complex in ethyl alcohol-water mixtures and the photometric determination of cobalt". Analyst. 72 (860): 478–481. Bibcode:1947Ana....72..478U. doi:10.1039/AN9477200478. PMID 18917685.
  18. ^Stewart, J.C. (1980). "Colorimetric determination of phospholipids with ammonium ferrothiocyanate". Anal. Biochem. 104 (1): 10–14. doi:10.1016/0003-2697(80)90269-9. PMID 6892980.

Salts and covalent derivatives of the cyanide ion

4CN, N
Ti V Cr(CN)3−
Mn Fe(CN)2,
Ge As(CN)

Zr Nb Mo(CN)4−
Tc Ru Rh Pd(CN)
Sn Sb(CN)
*Hf Ta W Re Os Ir Pt(CN)2−
Po At Rn
Fr Ra **Rf Db Sg Bh Hs Mt Ds Rg Cn Nh Fl Mc Lv Ts Og
Pr Nd Pm Sm(CN)
Tb Dy(CN)
Er Tm Yb(CN)
Np Pu Am Cm Bk Cf Es Fm Md No Lr

Element scn


Element Pilsen: Element Materials Technology


You will also be interested:


1189 1190 1191 1192 1193